Ubaldo Miranda
General Practice · Kissimmee, FLNPI 1366916231
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Bayer accounts for 62.9% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $331, more than ten times the $29 reported in 2021.
Across 38 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$529
- Hologic Sales And Service, LLC$67
- Amgen$47
- GSK$44
- Novo Nordisk$39
- Insightec,inc$30
- plus $85 from 5 others
Across 182 payments — averaging $2314.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$237K
- Regeneron$122K
- AstraZeneca$39K
- CSL Behring$23K
What the payments were for
- Food & beverage$840100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 22 | $529 |
| Hologic Sales And Service, LLC | 3 | $67 |
| Amgen(2 entities) | 2 | $47 |
| GSK | 2 | $44 |
| Novo Nordisk | 2 | $39 |
| Insightec,inc | 1 | $30 |
| Merck | 1 | $22 |
| Gilead | 1 | $18 |
| Dexcom, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 2 | $15 |
How this compares
$840 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 66 | $49,821 |
| FarxigaDapagliflozin Propanediol | 76 | $41,198 |
| JanumetSitagliptin Phos/Metformin Hcl | 63 | $31,972 |
| OzempicSemaglutide | 29 | $26,081 |
| JanuviaSitagliptin Phosphate | 30 | $22,310 |
| EliquisApixaban | 19 | $14,875 |
| XareltoRivaroxaban | 16 | $14,544 |
| MounjaroTirzepatide | 11 | $8,423 |
| Diclofenac Sodium | 99 | $2,066 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $1,778 |
| Novolog FlexpenInsulin Aspart | 17 | $1,670 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $993 |
| Atorvastatin Calcium | 127 | $840 |
| Nifedipine ErNifedipine | 29 | $798 |
| Losartan Potassium | 73 | $704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia | $22 | $54,28193 claims |
| BayerKerendia | $529 | $49,82166 claims |
| Novo NordiskOzempic | $39 | $26,08129 claims |
| Lilly USA, LLCMounjaro | $15 | $8,42311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.
Other general practice in Kissimmee
- Miguel Melendez MunozKissimmee$25K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Sarah JockinTampa$308K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
- Florencia ZiemkeWest Palm Beach$208K
- Ausberto HidalgoPembroke Pines$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.